Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Bautista, Oliver
216  Ergebnisse:
Personensuche X
?
1

Safety, efficacy, and immunogenicity of a replication-defec..:

Das, Rituparna ; Blázquez-Gamero, Daniel ; Bernstein, David I...
The Lancet Infectious Diseases.  23 (2023)  12 - p. 1383-1394 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Effectiveness, immunogenicity, and safety of the quadrivale..:

Maldonado, Ivette ; Plata, Manuel ; Gonzalez, Mauricio...
Human Vaccines & Immunotherapeutics.  18 (2022)  5 - p. , 2022
Link: https://doi.org/10.1080/..
 
?
3

1048. Double-Blind, Randomized, Placebo-Controlled Phase 2b..:

Das, Rituparna ; Blazquez-Gamero, Daniel ; Bernstein, David I...
Open Forum Infectious Diseases.  8 (2021)  Supplement_1 - p. S615-S616 , 2021
Link: https://doi.org/10.1093/..
 
?
4

Design of a Phase III immunogenicity and safety study evalu..:

Teppler, Hedy ; Bautista, Oliver ; Flores, Sheryl..
Contemporary Clinical Trials.  105 (2021)  - p. 106403 , 2021
Link: https://doi.org/10.1016/..
 
?
5

Long-term immunogenicity, effectiveness, and safety of nine..:

Olsson, Sven-Eric ; Restrepo, Jaime Alberto ; Reina, Julio Cesar...
Papillomavirus Research.  10 (2020)  - p. 100203 , 2020
Link: https://doi.org/10.1016/..
 
?
6

Final analysis of a 14-year long-term follow-up study of th..:

Kjaer, Susanne K. ; Nygård, Mari ; Sundström, Karin...
EClinicalMedicine.  23 (2020)  - p. 100401 , 2020
Link: https://doi.org/10.1016/..
 
?
7

Long-term effectiveness of the nine-valent human papillomav..:

Kjaer, Susanne K. ; Nygård, Mari ; Sundström, Karin...
Human Vaccines & Immunotherapeutics.  17 (2020)  4 - p. 943-949 , 2020
Link: https://doi.org/10.1080/..
 
?
8

Phase 1 Clinical Trial of a Conditionally Replication-Defec..:

Adler, Stuart P ; Lewis, Nicole ; Conlon, Anthony...
The Journal of Infectious Diseases.  220 (2019)  3 - p. 411-419 , 2019
Link: https://doi.org/10.1093/..
 
?
9

Phase 1 Clinical Trial of a Replication-Defective Human Cyt..:

Adler, Stuart ; Lewis, Nicole ; Conlon, Anthony...
Open Forum Infectious Diseases.  4 (2017)  suppl_1 - p. S308-S309 , 2017
Link: https://doi.org/10.1093/..
 
?
10

Intention-to-prevent analyses for estimating human papillom..:

Saah, Alfred ; Bautista, Oliver ; Luxembourg, Alain.
Contemporary Clinical Trials Communications.  7 (2017)  - p. 189-193 , 2017
Link: https://doi.org/10.1016/..
 
?
11

Design of a large outcome trial for a multivalent human pap..:

Luxembourg, Alain ; Bautista, Oliver ; Moeller, Erin..
Contemporary Clinical Trials.  42 (2015)  - p. 18-25 , 2015
Link: https://doi.org/10.1016/..
 
?
12

Safety and immunogenicity of a 9-valent HPV vaccine in fema..:

Garland, Suzanne M. ; Cheung, Tak-Hong ; McNeill, Shelly...
Vaccine.  33 (2015)  48 - p. 6855-6864 , 2015
Link: https://doi.org/10.1016/..
 
?
13

Safety, immunogenicity, and efficacy of quadrivalent human ..:

Muñoz, Nubia ; Manalastas Jr, Ricardo ; Pitisuttithum, Punee...
The Lancet.  373 (2009)  9679 - p. 1949-1957 , 2009
Link: https://doi.org/10.1016/..
 
?
14

Over‐ruling a group sequential boundary—a stopping rule ver..:

Lan, K. K. Gordon ; Lachin, John M. ; Bautista, Oliver
Statistics in Medicine.  22 (2003)  21 - p. 3347-3355 , 2003
Link: https://doi.org/10.1002/..
 
?
15

Design of a phase III efficacy, immunogenicity, and safety ..:

Giuliano, Anna R. ; Wilkin, Timothy ; Bautista, Oliver M....
Contemporary Clinical Trials.  115 (2022)  - p. 106592 , 2022
Link: https://doi.org/10.1016/..
 
1-15